Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $98.00

Mirum Pharmaceuticals (NASDAQ:MIRM) had its target price lifted by Stifel Nicolaus from $92.00 to $98.00 in a research note published on Tuesday morning,Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

Other equities research analysts have also recently issued research reports about the stock. Leerink Partners set a $100.00 target price on shares of Mirum Pharmaceuticals in a research report on Wednesday, December 10th. Evercore ISI boosted their price objective on shares of Mirum Pharmaceuticals from $89.00 to $94.00 and gave the company an “outperform” rating in a report on Monday, December 8th. Robert W. Baird increased their target price on shares of Mirum Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a research report on Monday, December 8th. HC Wainwright lifted their price target on shares of Mirum Pharmaceuticals from $80.00 to $81.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Finally, Raymond James Financial reiterated a “strong-buy” rating and issued a $110.00 price target on shares of Mirum Pharmaceuticals in a research note on Thursday, December 11th. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $96.50.

Mirum Pharmaceuticals Price Performance

Mirum Pharmaceuticals stock opened at $70.28 on Tuesday. The company has a market capitalization of $3.61 billion, a price-to-earnings ratio of -81.72 and a beta of 0.42. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06. Mirum Pharmaceuticals has a 12 month low of $36.88 and a 12 month high of $78.54. The stock’s 50 day moving average is $70.38 and its 200-day moving average is $64.23.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Tuesday, November 4th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The business had revenue of $133.01 million during the quarter, compared to analysts’ expectations of $130.11 million. During the same period last year, the firm posted ($0.30) EPS. The firm’s revenue for the quarter was up 47.1% compared to the same quarter last year. Equities research analysts expect that Mirum Pharmaceuticals will post -1.43 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. MCF Advisors LLC lifted its stake in Mirum Pharmaceuticals by 76.4% during the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after purchasing an additional 185 shares during the last quarter. Quantbot Technologies LP acquired a new position in shares of Mirum Pharmaceuticals during the 3rd quarter worth $33,000. Quarry LP acquired a new position in shares of Mirum Pharmaceuticals during the 3rd quarter worth $41,000. CWM LLC lifted its position in shares of Mirum Pharmaceuticals by 30.8% during the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock worth $50,000 after buying an additional 161 shares during the last quarter. Finally, Comerica Bank boosted its stake in Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after buying an additional 278 shares in the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.